- $106.64m
- $100.07m
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA
Brief: Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application
Israel's PolyPid Q4 EPS improves on lower R&D expenses
Brief: PolyPid Q4 Net Income USD -8.5 Million
Brief: Polypid Names Medtech Veteran Brooke Story as Board Chairman
Brief: Polypid Announces Positive FDA Pre-NDA Meeting Minutes
Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln
Brief: PolyPid Clears Israeli Health Ministry GMP Inspection, Nears Commercial Manufacturing for D-PLEX
PolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
Brief: PolyPid Q2 Net Income USD -10 Million
PolyPid Ltd expected to post a loss of 55 cents a share - Earnings Preview
PolyPid rises after treatment to prevent surgical site infections meets late-stage trial goal
Brief: PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial
PolyPid Ltd reports results for the quarter ended March 31 - Earnings Summary
Brief: Polypid Q1 Net Income USD -8.3 Million
PolyPid Ltd expected to post a loss of 80 cents a share - Earnings Preview